Structure Therapeutics (NASDAQ:GPCR) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Structure Therapeutics (NASDAQ:GPCR) from a sell rating to a strong sell rating in a research note released on Saturday,Wall Street Zen reports.

A number of other equities research analysts also recently commented on the company. Citigroup reiterated a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Weiss Ratings lowered Structure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 18th. HC Wainwright reaffirmed a “buy” rating on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a research report on Friday, August 7th. Finally, Citizens Jmp restated a “market outperform” rating and set a $110.00 price objective on shares of Structure Therapeutics in a report on Wednesday, September 9th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $110.91.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR opened at $27.59 on Friday. The stock has a market cap of $1.92 billion, a price-to-earnings ratio of -27.59 and a beta of -1.30. The company has a 50 day moving average of $44.25 and a 200-day moving average of $45.51. Structure Therapeutics has a one year low of $25.59 and a one year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities research analysts anticipate that Structure Therapeutics will post -1.87 earnings per share for the current year.

Institutional Trading of Structure Therapeutics

Hedge funds have recently bought and sold shares of the stock. Sterling Capital Management LLC acquired a new position in shares of Structure Therapeutics during the first quarter worth about $28,000. IFP Advisors Inc acquired a new stake in Structure Therapeutics in the 2nd quarter valued at approximately $46,000. Assetmark Inc. lifted its stake in Structure Therapeutics by 21.4% in the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after acquiring an additional 449 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in Structure Therapeutics in the 1st quarter valued at approximately $329,000. Finally, Cetera Investment Advisers boosted its position in Structure Therapeutics by 17.0% during the 1st quarter. Cetera Investment Advisers now owns 7,720 shares of the company’s stock worth $372,000 after acquiring an additional 1,124 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic and cardiopulmonary diseases. The company uses structure-based drug discovery and related technologies to identify therapies intended to address conditions with significant unmet medical needs.

Its lead product candidate is GSBR-1290, an investigational oral small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor being developed for obesity and type 2 diabetes.